Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

Let's decide whether AbbVie is a buy. In the pharmaceutical business ... $10.1 billion for ImmunoGen, and $8.7 billion for Cerevel Therapeutics.

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

If recent large acquisitions such as ImmunoGen or Cerevel are not successfully integrated, the business’ financial performance and strategic priorities may suffer. AbbVie is a stellar business ...

AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovarian cancer drug.